News
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.
Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...
CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...
5d
Zacks.com on MSNBAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
11h
Fintel on MSNTruist Securities Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy RecommendationFintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...
Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you ...
Despite some near-term revenue growth, HRTX's future is uncertain. Click here to find out why HRTX stock is a Hold.
Q1 2025 delivered first positive adjusted EBITDA result since 2021 and guided to a break-even adjusted EBITDA result for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results